NYSE:MTNB
Matinas BioPharma Holdings, Inc.
A clinical-stage biopharma developer targeting autoimmune diseases with a proprietary platform reliant on external capital for R&D expansion.
Key Metrics
Investment Thesis
Bull Case
MTNB offers high-risk, high-reward potential through its diverse pipeline of late-stage autoimmune therapies that could generate substantial value upon approval. The company's proprietary platform provides a technological edge that may lead to faster time-to-market compared to competitors in the crowded immunology space. If successful commercialization occurs, the return on invested capital from current cash reserves and future financing could be transformative for shareholders.
Bear Case
The sustained annual losses exceeding $24M and declining revenue trend pose a significant threat to long-term viability without successful product launches. High dependency on external capital means the stock is vulnerable to market downturns that restrict access to equity or debt financing. The lack of profitable operations and minimal current cash generation from sales makes the company's valuation highly speculative.
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company focused on developing novel treatments for autoimmune diseases and orphan conditions, primarily serving the North American market. The company leverages its proprietary platform to advance multiple candidates through late-stage clinical trials, aiming to address significant unmet medical needs in immunology and oncology. With limited current revenue streams, the firm relies heavily on strategic partnerships and financing to fund its extensive research and development pipeline.
Analysis
Management Discussion
Recent financial performance shows a widening net loss from -$21.0M in 2022 to -$24.3M in 2024, driven by escalating research and development costs of $11.4M and general administrative expenses of $8.7M. Despite minimal revenue growth from $3.2M in 2022 to $1.1M in 2023, the company has maintained a positive cash position with $7.5M in cash and equivalents, supported by significant financing activities totaling $9.2M.
Industry Overview
The global biopharmaceutical industry for autoimmune diseases is characterized by intense competition among major players like AbbVie and Pfizer, driving rapid innovation but also high development costs. Regulatory pathways remain stringent, requiring extensive clinical data to prove efficacy and safety before market entry. The sector offers significant opportunities for niche innovators who can differentiate their therapies through novel mechanisms of action.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $3.2M | $1.1M | — |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $3.2M | $1.1M | — |
| Operating Expenses | $27.8M | $24.9M | — |
| Operating Income | $-24.6M | $-23.8M | $-24.6M |
| R&D | $16.7M | $14.5M | $11.4M |
| G&A | $11.1M | $10.4M | $8.7M |
| Stock-Based Comp | $5.2M | $4.9M | $3.2M |
| D&A | $337.0K | $385.0K | $365.0K |
| Depreciation | $5.0K | $59.0K | — |
| Other OpEx | $0 | $0 | — |
| Non-Operating Income | $0 | $0 | $262.0K |
| Pre-Tax Income | $-24.6M | $-23.8M | $-24.3M |
| Income Tax | $-3.6M | $-824.0K | $-80.0K |
| Continuing Ops | $-21.0M | $-22.9M | $-24.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-21.0M | $-22.9M | $-24.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-21.0M | $-22.9M | $-24.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $34.5M | $15.5M | $8.0M |
| Cash & Equivalents | $6.8M | $4.8M | $7.3M |
| Marketable Securities | $21.9M | $9.0M | — |
| Prepaid Expenses | $5.7M | $1.7M | $691.0K |
| Other Current Assets | $50.0K | $50.0K | $50.0K |
| Long-Term Assets | $10.3M | $9.6M | $4.6M |
| PP&E (Net) | $2.1M | $1.9M | $468.0K |
| Intangibles | $3.0M | $3.0M | $2.3M |
| Goodwill | $1.3M | $1.3M | — |
| Operating Leases | $3.6M | $3.1M | $1.7M |
| Other LT Assets | $230.0K | $221.0K | $208.0K |
| Total Assets | $44.8M | $25.1M | $12.6M |
| Current Liabilities | $4.3M | $2.6M | $2.7M |
| Accounts Payable | $618.0K | $514.0K | $95.0K |
| Current Leases | $562.0K | $656.0K | $761.0K |
| Other Current Liab | $7.0K | $5.0K | $9.0K |
| Long-Term Liabilities | $3.9M | $3.2M | $2.4M |
| LT Operating Leases | $3.5M | $2.9M | $2.1M |
| Other LT Liab | $363.0K | $359.0K | $269.0K |
| Total Liabilities | $8.2M | $5.9M | $5.1M |
| Shareholders' Equity | $36.6M | $19.2M | $7.6M |
| Paid-In Capital | $190.1M | $195.0M | $207.4M |
| Retained Earnings | $-152.6M | $-175.6M | $-199.8M |
| AOCI | $-824.0K | $-221.0K | — |
| Total L&E | $44.8M | $25.1M | $12.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-21.0M | $-22.9M | $-24.3M |
| Non-Cash Adjustments | $-1.8M | $14.0M | $9.7M |
| Working Capital Changes | $3.6M | $-6.3M | $-1.3M |
| Cash from Operations | $-19.2M | $-15.3M | $-15.9M |
| Capital Expenditures | $892.0K | $218.0K | — |
| Cash from Investing | $4.9M | $13.2M | $9.2M |
| Cash from Financing | $79.0K | $-7.0K | $9.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-14.2M | $-2.0M | $2.5M |
| Beginning Cash | $21.3M | $7.1M | $5.0M |
| Ending Cash | $7.1M | $5.0M | $7.5M |
Frequently Asked Questions
How does Matinas BioPharma Holdings, Inc. make money?
The company's financials reflect operations centered on research and development (R&D) of proprietary drug candidates, likely including late-stage programs in immunology and oncology. Revenue is derived from commercial sales of approved products or milestone payments from strategic licensing agreements, though current revenue is minimal compared to operating expenses. A significant portion of assets is tied up in intangible assets representing the value of these intellectual property portfolios.
What are the main risks for MTNB?
The company operates at a substantial net loss of $24.3M annually, indicating a heavy reliance on external financing which could be difficult to secure in volatile markets. Cash burn rates are high with operating cash flow at -$15.9M, raising concerns about liquidity if new funding rounds fail to materialize. Clinical trial failures or regulatory rejections of their pipeline candidates would severely impact valuation and future capital requirements.
What is MTNB's competitive advantage?
The company possesses a proprietary technology platform designed to accelerate drug discovery and reduce development timelines for novel therapies. Their pipeline includes multiple late-stage candidates with potential blockbuster profiles, offering high upside if regulatory approval is achieved. Strong intellectual property protection across their autoimmune disease targets creates a defensive moat against generic competition.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.